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The prognosis of breast cancer has 
improved over time due to earlier diag-
noses as a result of screening programs 
and patient awareness and the increased 
use of more effective systemic therapies. 
Oncologists are more and more concerned 
with the long-term side effects of some 
anticancer treatments, which should be 
carefully evaluated. Aromatase inhibitors 
are associated with an increased risk of 
osteoporosis, tamoxifen is associated with 
uterine cancer and chemotherapy is asso-
ciated with myelodysplasia and secondary 
leukemia. In addition, long-term cardiac 
toxicity is an important issue in breast 
cancer survivors [1]. Since many patients 
with early-stage breast cancer can be cured 
by surgery and radiotherapy alone or with 
the addition of systemic therapy without 
cardiotoxicity, it is important that the ben-
efits associated with potential cardiotoxic 
regimens outweigh the risks of short-term 
and long-term toxicity. Left ventricular 
(LV) dysfunction has become a common 
cause of death in breast cancer survivors. 
Oncological and cardiac risk factors must 
be carefully evaluated when deciding on 
adjuvant treatment regimens for breast 
cancer.
Cancer survivors & long-term 
cardiotoxicity
It has long been known that chemotherapy 
and radiotherapy – either alone or in com-
bination – exposes a patient to an increased 
risk of cardiac morbidity and mortality [2]. 
Anti-HER2 therapies such as trastuzumab 
are also associated with cardiotoxicity [3]. 
Anthracycline-related cardiotoxicity (car-
diotoxicity type 1) is generally considered 
to be irreversible, cumulative and dose-
dependent; type 2 cardiotoxicity related 
to trastuzumab is more reversible.
Long-term follow-up of 51,246 patients 
suffering from T1a,bN0M0 breast cancer 
registered in the SEER Program from 1988 
to 2001 revealed that more patients died 
from heart disease (n = 1727) than from 
breast cancer (n = 1340) [4]. This study also 
revealed that the risk of dying from other 
causes was five-times higher than the risk 
of dying from breast cancer 10 years after 
diagnosis. It is important to keep in mind 
that in the general population a woman 
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“A careful cardiac and oncological risk factor evaluation should allow for 
more individualized treatment planning; it is important to better predict 
patients at risk for cardiotoxicity.”
“The prognosis of breast cancer 
has improved over time due to 
earlier diagnoses as a result of 
screening programs and patient 
awareness and the increased use 
of more effective systemic 
therapies.”
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was 3.9-times more likely to die from cardiac 
heart disease than from breast cancer in 2009 [5]. 
However, age is an important risk factor: in the 
youngest group of patients aged 25–44 years, 
women were about three-times more likely to die 
from breast cancer than cardiac heart disease. 
Only in postmenopausal women was the risk of 
dying from cardiac heart disease higher than the 
risk of dying from breast cancer.
Cardio-oncology
Cardio-oncology is a new subspeciality in the 
field of cardiology in which cardiologists join a 
multidisciplinary team devoted to treating breast 
cancer. Before starting treatment, it is important 
to identify patients at increased risk for cardiac 
toxicity; age is not the only risk factor [6]. Data 
suggest an association between cardiovascular 
risk factors such as a history of hypertension, 
diabetes or known coronary artery disease 
and cardiotoxicity of anticancer therapy [7,8]. 
Known risk factors for trastuzumab-associated 
cardiac toxicity also include a lower screen-
ing LV ejection fraction (LVEF) and a lower 
post-anthracycline LVEF [9].
Alternative less cardiotoxic regimens should 
be considered according to oncological risk if 
the patients present a high cardiac risk, and more 
frequent cardiac monitoring is necessary in these 
patients if cardiotoxic drugs cannot be avoided.
Many unanswered questions
Nevertheless, many questions still remain. 
The European Association of Cardiovascular 
Imaging and Heart Failure  Association Cardiac 
Oncology Toxicity registry is a prospective, 
multicenter, observational research program of 
the European Society of Cardiology in breast 
cancer patients [10] intended for comprehensive 
data collection and evaluation. More than 13 
countries are involved in the pilot study, and all 
European countries will be invited to partici-
pate to the long-term registry. The registry will 
include information concerning the diagnosis 
and management of anticancer drug related car-
diotoxicity in breast cancer patients and, in par-
ticular, the tests performed routinely at baseline, 
during treatment and during follow-up. Clear 
guidelines for monitoring and therapy interrup-
tion exist in particular for adjuvant therapy with 
trastuzumab. Treatment by b-blockers and angi-
otensin-converting enzyme inhibitors or angio-
tensin receptor blockers is necessary in the case 
of asymptomatic decrease of LVEF. It has been 
reported that trastuzumab can be successfully 
reintroduced in many patients after interruption 
without observing a new event of cardiotoxic-
ity [11], which should also be c onfirmed in a large 
unselected patient population.
Who is eligible for this cardiac registry?
All breast cancer patients who will receive or are 
receiving potential cardiotoxic anticancer thera-
pies and who underwent a cardiologic imaging 
technique are eligible. Taratini et al. [12] observed 
a higher prevalence of hypertension, diabetes, 
renal dysfunction and dyslipidemia in patients 
older than 60 years compared with younger 
patients in a multicenter Italian trial evaluat-
ing trastuzumab-associated cardio toxicity. 
Poor cardiac outcome in an older patient 
population has also been reported by Chavez-
MacGregor et al. [13] in an even larger popula-
tion-based study using the SEER-Medicare and 
the Texas Cancer Registry-Medicare databases. 
These authors observed a very high rate of con-
gestive heart failure in women at least 66 years 
old who suffered from early-stage breast cancer 
and who were treated by chemotherapy.
What are the collected variables in the 
registry?
The following information will be collected 
from all patients: demographic characteristics, 
co-morbidities and risk factors for cardiovascular 
diseases, cancer history, current treatment and 
expected anticancer therapy including breast 
surgery, radiotherapy, chemotherapy, targeted 
therapy and endocrine therapy, clinical signs 
and symptoms of cardiotoxicity and results of 
monitoring tests including biomarkers such as 
troponin and BNP and cardiac imaging tech-
niques including echocardiography, stress tests, 
MUGA and MRI. The use of cardioprotective 
agents and the pharmacological treatments of 
cardiotoxicity will also be reported.
Is this registry just another registry?
The current project is just the first step of a much 
more ambitious project. Additional knowledge 
should be made available by the registry con-
cerning predisposing cardiac risk factors, the 
rate of subclinical LV dysfunction in the real 
world for the most frequently administered 
cardiotoxic anticancer agents, and transition to 
overt heart failure. In addition, the registry will 
further evaluate the clinical impact and outcome 
of anticancer drug related cardiotoxicity. This 
“The long-term cardiac 
morbidity and mortality 
benefits of this 
multidisciplinary 
cardio-oncology approach 
should be carefully 
evaluated.”
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project focuses on breast cancer, but the treat-
ment of other oncological diseases also involves 
cardiotoxic drugs. In the future, these cardio-
oncology clinics should be available for all can-
cer patients who are candidates for receiving 
 cardiotoxic drugs.
Preparing for the future
A careful cardiac and oncological risk factor 
evaluation should allow for more individualized 
treatment planning; it is important to better pre-
dict patients at risk for cardiotoxicity. The aim of 
this registry is to better understand the risk of car-
diac toxicity based on the patient’s characteristics 
prior to treatment and to use this information for 
better treatment planning in the future. Potential 
reversibility of cardiac toxicity also needs to be 
taken into account in particular if early detection 
is associated with the best chances for complete 
recovery after appropriate management.
Routinely measuring LVEF before, during 
and after adjuvant therapy, is standard of care 
for trastuzumab-based anticancer therapy but 
many other cardiotoxic drugs are used in the field 
of breast cancer. The aim of the registry is to also 
obtain better information concerning the routine 
cardiac monitoring when other agents are used 
in order to allow to define clear re commendation 
also for these other anticancer drugs.
We also need information concerning the use 
of biomarkers in addition to the use of imaging 
procedures. The potential benefits of biomark-
ers include earlier detection of cardiotoxicity, 
the assessment of physiopathology and the pre-
diction of outcomes. Currently, troponin and 
BNP are the most frequently used biomarkers, 
but other biomarkers will also likely be used in 
the near future. The sensitivity and specificity 
of biomarkers is a critical issue. If a standard 
cut-off value of BNP (>100 pg/ml) is used, many 
patients presenting later drug-related cardiotox-
icity will not be identified. On the other hand, 
decreasing the cut-off value is associated with 
many false-positive results [14].
One open question is the role of angiotensin-
converting enzyme inhibitors in the preven-
tion of trastuzumab-related cardiotoxicity [15]. 
b-blockers are other candidates for preventive 
treatments [16], and preventive treatments should 
also be evaluated. The role of preventive or early 
pharmacological interventions with b-blockers 
and/or angiotensin-converting enzyme inhibi-
tors has to be further clarified. Randomized 
t rials are already ongoing in this field [17].
Today, oncologists work together mainly to 
detect and manage cardiotoxicity, but cardiolo-
gists are rarely involved in the initial treatment 
planning. In the future, the development of 
cardio-oncology units should make it possible 
to include cardiologists in treatment planning. 
Strategies have been developed for decreasing 
cardiac events by adapting the treatments. For 
the systemic therapy of HER2-positive breast 
cancer, we have the choice of using less-cardi-
otoxic approaches (e.g., by not using anthracy-
clines or by using sequential regimens of chem-
otherapy followed by trastuzumab). A careful 
cardiological and oncological risk evaluation 
within a multidisciplinary team before starting 
any systemic therapy should become standard 
care in order to optimize the chances of recov-
ery without long-term cardiac side effects. This 
multidisciplinary approach may also help to 
define common strategies to address new forms 
of prevention and treatment of anticancer drug 
associated cardiotoxicity. The long-term cardiac 
morbidity and mortality benefits of this multi-
disciplinary cardio-oncology approach should 
be carefully evaluated.
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